As glucagon-like peptide-1 receptor agonists (GLP-1RAs) become first-line therapies for diabetes and obesity, their safety in patients with premalignant pancreatic lesions remains uncertain. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.